Monday, February 6, 2023
Google search engine
HomeMarketResultsInsider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) Major Shareholder Sells 34,801 Shares of...

Insider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) Major Shareholder Sells 34,801 Shares of Stock


Vir Biotechnology, Inc. (NASDAQ:VIRGet Rating) main shareholder Endurance (Cayman) Ltd Svf offered 34,801 shares of the inventory in a transaction on Monday, January ninth. The inventory was offered at a median value of $25.85, for a complete worth of $899,605.85. Following the transaction, the insider now straight owns 20,149,378 shares within the firm, valued at roughly $520,861,421.30. The sale was disclosed in a submitting with the SEC, which may be accessed by means of the SEC website. Main shareholders that personal not less than 10% of an organization’s shares are required to reveal their transactions with the SEC.

Endurance (Cayman) Ltd Svf additionally not too long ago made the next commerce(s):

  • On Friday, January sixth, Endurance (Cayman) Ltd Svf offered 66,179 shares of Vir Biotechnology inventory. The inventory was offered at a median value of $26.13, for a complete worth of $1,729,257.27.
  • On Tuesday, January third, Endurance (Cayman) Ltd Svf offered 8,177 shares of Vir Biotechnology inventory. The inventory was offered at a median value of $25.58, for a complete worth of $209,167.66.
  • On Tuesday, December twenty seventh, Endurance (Cayman) Ltd Svf offered 6,850 shares of Vir Biotechnology inventory. The inventory was offered at a median value of $25.59, for a complete worth of $175,291.50.
  • On Thursday, December twenty second, Endurance (Cayman) Ltd Svf offered 95,144 shares of Vir Biotechnology inventory. The inventory was offered at a median value of $26.07, for a complete worth of $2,480,404.08.
  • On Tuesday, December twentieth, Endurance (Cayman) Ltd Svf offered 104,026 shares of Vir Biotechnology inventory. The inventory was offered at a median value of $25.53, for a complete worth of $2,655,783.78.
  • On Monday, December fifth, Endurance (Cayman) Ltd Svf offered 8,831 shares of Vir Biotechnology inventory. The inventory was offered at a median value of $27.25, for a complete worth of $240,644.75.
  • On Friday, December 2nd, Endurance (Cayman) Ltd Svf offered 88,462 shares of Vir Biotechnology inventory. The inventory was offered at a median value of $27.47, for a complete worth of $2,430,051.14.
  • On Wednesday, November thirtieth, Endurance (Cayman) Ltd Svf offered 165,953 shares of Vir Biotechnology inventory. The shares had been offered at a median value of $27.85, for a complete worth of $4,621,791.05.
  • On Monday, November twenty eighth, Endurance (Cayman) Ltd Svf offered 37,989 shares of Vir Biotechnology inventory. The shares had been offered at a median value of $27.46, for a complete worth of $1,043,177.94.
  • On Friday, November twenty fifth, Endurance (Cayman) Ltd Svf offered 17,264 shares of Vir Biotechnology inventory. The inventory was offered at a median value of $27.21, for a complete transaction of $469,753.44.

Vir Biotechnology Buying and selling Up 1.6 %

NASDAQ VIR traded up $0.43 throughout buying and selling hours on Tuesday, reaching $26.52. The corporate’s inventory had a buying and selling quantity of 526,506 shares, in comparison with its common quantity of 593,369. The enterprise has a 50-day easy shifting common of $26.12 and a 200 day easy shifting common of $25.05. Vir Biotechnology, Inc. has a 52 week low of $18.05 and a 52 week excessive of $41.23. The inventory has a market cap of $3.53 billion, a PE ratio of three.12 and a beta of 0.15.

Vir Biotechnology (NASDAQ:VIRGet Rating) final issued its earnings outcomes on Thursday, November third. The corporate reported $1.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $1.29. The enterprise had income of $374.56 million in the course of the quarter, in comparison with the consensus estimate of $153.79 million. As a bunch, equities analysts predict that Vir Biotechnology, Inc. will put up 4.61 EPS for the present 12 months.

Institutional Traders Weigh In On Vir Biotechnology

Hedge funds have not too long ago made adjustments to their positions within the enterprise. Nisa Funding Advisors LLC raised its holdings in shares of Vir Biotechnology by 127.3% in the course of the second quarter. Nisa Funding Advisors LLC now owns 1,000 shares of the corporate’s inventory valued at $25,000 after shopping for an extra 560 shares over the last quarter. US Bancorp DE elevated its stake in shares of Vir Biotechnology by 175.1% in the course of the second quarter. US Bancorp DE now owns 982 shares of the corporate’s inventory valued at $25,000 after buying an extra 625 shares in the course of the interval. Wipfli Monetary Advisors LLC acquired a brand new place in shares of Vir Biotechnology in the course of the third quarter valued at roughly $25,000. SeaCrest Wealth Administration LLC acquired a brand new place in shares of Vir Biotechnology in the course of the second quarter valued at roughly $36,000. Lastly, Twin Lakes Capital Administration LLC acquired a brand new place in shares of Vir Biotechnology in the course of the third quarter valued at roughly $42,000. Institutional buyers personal 74.97% of the corporate’s inventory.

Analysts Set New Worth Targets

A number of equities analysts have not too long ago commented on VIR shares. SVB Leerink elevated their value goal on shares of Vir Biotechnology from $40.00 to $45.00 and gave the inventory an “outperform” score in a analysis report on Friday, November 4th. TheStreet raised shares of Vir Biotechnology from a “d” score to a “c-” score in a analysis report on Monday, October tenth. Morgan Stanley elevated their value goal on shares of Vir Biotechnology from $15.00 to $18.00 and gave the inventory an “underweight” score in a analysis report on Friday, November 4th. Lastly, Needham & Firm LLC lowered their value goal on shares of Vir Biotechnology from $35.00 to $32.00 and set a “purchase” score on the inventory in a analysis report on Friday, November 4th. One analyst has rated the inventory with a promote score, one has assigned a maintain score and three have assigned a purchase score to the inventory. In response to information from MarketBeat.com, the inventory presently has a consensus score of “Maintain” and a consensus goal value of $52.50.

Vir Biotechnology Firm Profile

(Get Rating)

Vir Biotechnology, Inc, a commercial-stage immunology firm, develops therapeutic merchandise to deal with and forestall severe infectious illnesses. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to deal with and forestall COVID-19 an infection underneath the Xevudy model; VIR-2218 and VIR-3434 for the therapy of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.

Learn Extra

Insider Buying and Selling by Quarter for Vir Biotechnology (NASDAQ:VIR)

This on the spot information alert was generated by narrative science expertise and monetary information from MarketBeat to be able to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial workforce previous to publication. Please ship any questions or feedback about this story to contact@marketbeat.com.

Earlier than you take into account Vir Biotechnology, you may need to hear this.

MarketBeat retains monitor of Wall Avenue’s top-rated and greatest performing analysis analysts and the shares they suggest to their purchasers each day. MarketBeat has recognized the five stocks that prime analysts are quietly whispering to their purchasers to purchase now earlier than the broader market catches on… and Vir Biotechnology wasn’t on the checklist.

Whereas Vir Biotechnology at present has a “Maintain” score amongst analysts, top-rated analysts consider these 5 shares are higher buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover



Source link

RELATED ARTICLES
- Advertisment -
Google search engine

Most Popular

Recent Comments